103 related articles for article (PubMed ID: 28406788)
1. Improving Patient-Centered Care by Assessing Patient Preferences for Multiple Sclerosis Disease-Modifying Agents: A Stated-Choice Experiment.
Carlin CS; Higuera L; Anderson S
Perm J; 2017; 21():16-102. PubMed ID: 28406788
[TBL] [Abstract][Full Text] [Related]
2. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
Bottomley C; Lloyd A; Bennett G; Adlard N
J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
[TBL] [Abstract][Full Text] [Related]
3. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
Poulos C; Kinter E; van Beek J; Christensen K; Posner J
Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
[TBL] [Abstract][Full Text] [Related]
4. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis.
Shingler SL; Swinburn P; Ali S; Perard R; Lloyd AJ
J Med Econ; 2013 Aug; 16(8):1036-42. PubMed ID: 23730944
[TBL] [Abstract][Full Text] [Related]
5. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.
Webb EJD; Meads D; Eskyte I; King N; Dracup N; Chataway J; Ford HL; Marti J; Pavitt SH; Schmierer K; Manzano A
Patient; 2018 Aug; 11(4):391-402. PubMed ID: 29313265
[TBL] [Abstract][Full Text] [Related]
7. Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.
Kremer IE; Evers SM; Jongen PJ; van der Weijden T; van de Kolk I; Hiligsmann M
PLoS One; 2016; 11(11):e0164862. PubMed ID: 27812117
[TBL] [Abstract][Full Text] [Related]
8. Patients' preferences and willingness-to-pay for disease-modifying therapies.
Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
[TBL] [Abstract][Full Text] [Related]
10. An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries.
Visser LA; Huls SPI; Uyl-de Groot CA; de Bekker-Grob EW; Redekop WK
J Neurol Sci; 2021 Sep; 428():117587. PubMed ID: 34364148
[TBL] [Abstract][Full Text] [Related]
11. An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis.
Bauer B; Brockmeier B; Devonshire V; Charbonne A; Wach D; Hendin B
Neurodegener Dis Manag; 2020 Dec; 10(6):369-382. PubMed ID: 32873160
[No Abstract] [Full Text] [Related]
12. Patient preferences for Interferon-beta in Iran: A discrete choice experiment.
Rahimi F; Rasekh HR; Abbasian E; Peiravian F; Etemadifar M; Ashtari F; Sabzghabaee AM; Amirsadri MR
PLoS One; 2018; 13(3):e0193090. PubMed ID: 29590134
[TBL] [Abstract][Full Text] [Related]
13. Understanding Patient Preferences in Medication Nonadherence: A Review of Stated Preference Data.
Laba TL; Essue B; Kimman M; Jan S
Patient; 2015 Oct; 8(5):385-95. PubMed ID: 25404203
[TBL] [Abstract][Full Text] [Related]
14. A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis.
Rothery C; Bojke L; Richardson G; Bojke C; Moverley A; Coates L; Thorp L; Waxman R; Helliwell P
Clin Rheumatol; 2016 Dec; 35(12):2967-2974. PubMed ID: 27796664
[TBL] [Abstract][Full Text] [Related]
15. Prescribing of disease modifying agents in older adults with multiple sclerosis.
Talwar A; Earla JR; Hutton GJ; Aparasu RR
Mult Scler Relat Disord; 2022 Jan; 57():103308. PubMed ID: 35158421
[TBL] [Abstract][Full Text] [Related]
16. What Do Patients Want from Otolaryngologists? A Discrete Choice Experiment.
Naunheim MR; Rathi VK; Naunheim ML; Alkire BC; Lam AC; Song PC; Shrime MG
Otolaryngol Head Neck Surg; 2017 Oct; 157(4):618-624. PubMed ID: 28675119
[TBL] [Abstract][Full Text] [Related]
17. Patient preferences for treatment of low back pain-a discrete choice experiment.
Kløjgaard ME; Manniche C; Pedersen LB; Bech M; Søgaard R
Value Health; 2014 Jun; 17(4):390-6. PubMed ID: 24968999
[TBL] [Abstract][Full Text] [Related]
18. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
Mühlbacher A; Bethge S
Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
[TBL] [Abstract][Full Text] [Related]
19. Eliciting patients' preferences for epilepsy diagnostics: a discrete choice experiment.
Wijnen BF; de Kinderen RJ; Colon AJ; Dirksen CD; Essers BA; Hiligsmann M; Leijten FS; Ossenblok PP; Evers SM
Epilepsy Behav; 2014 Feb; 31():102-9. PubMed ID: 24389020
[TBL] [Abstract][Full Text] [Related]
20. Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.
Morel T; Aymé S; Cassiman D; Simoens S; Morgan M; Vandebroek M
Orphanet J Rare Dis; 2016 May; 11(1):70. PubMed ID: 27225337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
